Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.

ABSTRACT: Treatment of cancer patients has been recently revolutionized by the application of various immunotherapeutics. However, the response rates are still limited ranging between approximately 20 and 40% suggesting that combinations of immunotherapy with conventional treatment, like chemotherapy, radiation, epigenetic modulators, targeted therapies using small molecules as well as other (immuno) therapeutics, might be an option to increase systemic anti-tumor immunity. It is postulated that different non-immune based therapies in combination with immunotherapies could reprogram the immune suppressive tumor microenvironment and enhance the immunogenicity of tumor cells leading to an improved therapeutic efficacy and a better patients' outcome. Despite there exist various examples of increased ob

SUBMITTER: Seliger B 

PROVIDER: S-EPMC6538766 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature